Raat Willem, Mamouris Pavlos, Mathieu Chantal, Goderis Geert, Vaes Bert
Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium.
Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium.
Prim Care Diabetes. 2025 Feb;19(1):29-34. doi: 10.1016/j.pcd.2024.10.007. Epub 2024 Oct 31.
To assess the prevalence of atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), and chronic kidney disease (CKD) among patients with type 2 diabetes (T2D) in Belgium. To analyze trends in medication use and adherence to guidelines from 2019 to 2023.
We conducted a retrospective cross-sectional analysis using data from the Intego primary care database, encompassing records from 431 general practitioners. We identified adults with T2D through diagnostic codes and glycated hemoglobin levels and analyzed subgroups with ASCVD, HF, and CKD for trends in medication use, particularly SGLT2 inhibitors (SGLT2-i) and GLP-1 receptor agonists (GLP-1).
The T2D population increased from 20,766 in 2019 to 21,764 in 2023. The prevalence of ASCVD, HF, and CKD among T2D patients slightly increased to 27 %, 6.7 %, and 23.7 % by 2023 (from 25.2 %, 4.9 % and 21.5 % respectively). Medication prescription trends showed a tripling of SGLT2-i and GLP-1 prescribing in the study period to 6.2 % and 11.5 % respectively. Despite these increases, only 7.5 % of eligible patients received these medications as of 2023.
The study highlights a growing burden of ASCVD, HF, and CKD among T2D patients in Belgium and an increase in the use of guideline-recommended medications. However, there remains a substantial gap in the optimal use of these therapies, indicating a need for improved implementation of clinical guidelines in primary care.
评估比利时2型糖尿病（T2D）患者中动脉粥样硬化性心血管疾病（ASCVD）、心力衰竭（HF）和慢性肾脏病（CKD）的患病率。分析2019年至2023年药物使用趋势及指南遵循情况。
我们使用来自Intego初级保健数据库的数据进行回顾性横断面分析，该数据库包含431名全科医生的记录。我们通过诊断编码和糖化血红蛋白水平识别成年T2D患者，并分析患有ASCVD、HF和CKD的亚组的药物使用趋势，特别是钠-葡萄糖协同转运蛋白2抑制剂（SGLT2-i）和胰高血糖素样肽-1受体激动剂（GLP-1）。
T2D患者人数从2019年的20,766人增加到2023年的21,764人。到2023年，T2D患者中ASCVD、HF和CKD的患病率分别从25.2%、4.9%和21.5%略有上升至27%、6.7%和23.7%。药物处方趋势显示，在研究期间，SGLT2-i和GLP-1的处方量分别增加了两倍，达到6.2%和11.5%。尽管有这些增加，但截至2023年，只有7.5%的符合条件的患者接受了这些药物治疗。
该研究凸显了比利时T2D患者中ASCVD、HF和CKD负担的增加以及指南推荐药物使用的增加。然而，这些疗法的最佳使用仍存在很大差距，表明需要在初级保健中更好地实施临床指南。
